Who’s Hired? Endo Names New CEO
While Mylan and Pfizer’s Viatris Builds Its Leadership Team
Endo has named a new CEO and CFO, while Mylan and Pfizer’s Viatris has found its CFO and announced its full roster of board members. Meanwhile, Assogenerici names the leaders of its value added medicines sector group, law firm Fish & Richardson gets a new CEO and France appoints a new health minister.
You may also be interested in...
Industry veteran Paul Bisaro has joined the board of TherapeuticsMD and Mylan has announced new Viatris appointments, while Amneal brings in a new CFO at the same time as Fresenius Kabi’s biosimilars head exits the company.
Set to take charge of the company on 6 March, Endo's incoming chief Blaise Coleman must tackle Endo's multi-billion-dollar debt and steer the firm back to profitability after several years of significant losses.
With Endo’s CEO Paul Campanelli intending to step down for personal reasons, the US brands and generics player’s board has started to look for external and internal candidates to take over.